Skip to main content
OrthoVellum
Knowledge Hub

Study

  • Topics
  • MCQs
  • ISAWE
  • Operative Surgery
  • Flashcards

Company

  • About Us
  • Editorial Policy
  • Contact
  • FAQ
  • Blog

Legal

  • Terms of Service
  • Privacy Policy
  • Cookie Policy
  • Medical Disclaimer
  • Copyright & DMCA
  • Refund Policy

Support

  • Help Center
  • Accessibility
  • Report an Issue
OrthoVellum

© 2026 OrthoVellum. For educational purposes only.

Not affiliated with the Royal Australasian College of Surgeons.

Lumbar Disc Arthroplasty (Total Disc Replacement)

Back to Topics
Contents
0%

Lumbar Disc Arthroplasty (Total Disc Replacement)

Comprehensive guide to lumbar total disc replacement - indications, contraindications, implant designs, surgical technique, complications, and outcomes for FRCS exam preparation

complete
Updated: 2025-12-25
High Yield Overview

LUMBAR DISC ARTHROPLASTY

Motion Preservation Alternative to Fusion | Strict Patient Selection | Anterior Approach

L4-S1FDA-approved levels
Under 60Ideal age range
5-15°Preserved ROM per level
Non-infvs fusion in RCTs

IMPLANT DESIGN CATEGORIES

Mobile-bearing
PatternFree polyethylene core (Charite)
TreatmentUnconstrained motion
Fixed-bearing
PatternFixed poly core (ProDisc-L)
TreatmentSemi-constrained
Metal-on-metal
PatternNo polyethylene (Maverick)
TreatmentMetallosis concerns

Critical Must-Knows

  • Primary indication = single or two-level DDD (L4-S1) with discogenic pain, failed conservative care
  • Contraindications: Facet arthropathy, spondylolisthesis, previous surgery at level, osteoporosis, stenosis
  • Motion preservation theoretically reduces adjacent segment disease (ASD) compared to fusion
  • Anterior retroperitoneal approach (ALIF) required - major vascular structures at risk
  • Patient selection critical - strict criteria essential for good outcomes

Examiner's Pearls

  • "
    Ideal candidate: young (under 60), single-level L4-5 or L5-S1, no facet disease, good bone quality
  • "
    Cannot perform if previous posterior surgery at same level (scar tissue)
  • "
    Vascular injury (iliac vessels) is main intraoperative risk
  • "
    Retrograde ejaculation risk from hypogastric plexus injury at L5-S1
  • "
    Non-inferior to fusion in FDA IDE trials (Charite, ProDisc-L)

Clinical Imaging

Imaging Gallery

Five-type classification system of vertebral endplate morphology with anatomical illustrations and corresponding lateral radiographs (Type I-V: Flat, Hooked, Concave, Convex, Combined)
Click to expand
Five-type classification system of vertebral endplate morphology with anatomical illustrations and corresponding lateral radiographs (Type I-V: Flat, Credit: Yue JJ et al. via SAS J via Open-i (NIH) (Open Access (CC BY))
Four-panel lateral lumbar spine radiographs showing pre-operative degenerative disc disease and post-operative appearance with total disc replacement implant in situ
Click to expand
Four-panel lateral lumbar spine radiographs showing pre-operative degenerative disc disease and post-operative appearance with total disc replacement Credit: Marchi L et al. via Int J Spine Surg via Open-i (NIH) (Open Access (CC BY))

Critical Lumbar TDR Exam Points

Strict Indications

Single or two-level DDD (L4-5, L5-S1 only). Discogenic pain confirmed by provocative discography or MRI. Failed conservative treatment over 6 months. No significant facet arthropathy (excludes patient). Maintained disc height (at least 4mm). Age typically under 60 years.

Critical Contraindications

Absolute: Facet arthropathy (pain generator not addressed), spondylolisthesis greater than Grade I, spinal stenosis, previous surgery at target level, osteoporosis (T-score less than negative 1.5), active infection, pregnancy. Relative: Obesity (BMI over 35), metal allergy, more than two levels.

Vascular Approach Risks

Anterior retroperitoneal approach required. At L5-S1: access between aortic bifurcation and left common iliac vein. At L4-5: requires left common iliac vein mobilization (higher risk). Vascular injury is most feared complication - access surgeon recommended. Retrograde ejaculation from sympathetic plexus injury (1-5% at L5-S1).

Motion Preservation Rationale

Fusion transfers stress to adjacent segments, theoretically accelerating adjacent segment disease (ASD). TDR preserves 5-15° range of motion per level, maintaining more physiologic biomechanics. However, long-term ASD reduction benefit remains theoretical - data still evolving beyond 10 years.

At a Glance

Lumbar total disc replacement (TDR) is a motion-preserving alternative to fusion for single or two-level degenerative disc disease at L4-S1 in carefully selected patients, theoretically reducing adjacent segment disease by preserving 5-15° range of motion per level. The ideal candidate is under 60 years, has isolated discogenic pain confirmed by MRI or discography, no significant facet arthropathy, and good bone quality—the mnemonic "FOSSILS" captures contraindications: Facet arthropathy, Osteoporosis, Spondylolisthesis, Stenosis, Infection, Levels (greater than 2), Surgery at level. The anterior retroperitoneal approach places major vascular structures at risk, with iliac vessel injury being the most feared complication; retrograde ejaculation from hypogastric plexus injury occurs in 1-5% at L5-S1. FDA IDE trials (Charité, ProDisc-L) demonstrate non-inferiority to fusion, though long-term adjacent segment disease reduction remains theoretical.

Mnemonic

FOSSILSTDR Contraindications

F
Facet arthropathy
Major pain generator not addressed by TDR
O
Osteoporosis
Endplate subsidence risk (T-score less than negative 1.5)
S
Spondylolisthesis
Instability contraindicated (greater than Grade I)
S
Stenosis (spinal)
Needs decompression, not motion preservation
I
Infection
Active or previous discitis at target level
L
Levels (more than 2)
Multi-level disease not FDA approved
S
Surgery (previous at level)
Scarred disc space, altered anatomy

Memory Hook:FOSSILS = Ancient, outdated patients for disc arthroplasty - these patients need fusion instead!

Mnemonic

YOUNG-DISCIdeal TDR Candidate

Y
Young (under 60 years)
Longer expected benefit from motion preservation
O
One or two levels only
Typically L4-5 or L5-S1, FDA-approved levels
U
Unchanged facets
No facet arthropathy or posterior element disease
N
No previous surgery at level
Virgin disc space, no scar tissue
G
Good bone quality
Normal BMD, no osteoporosis (T-score greater than negative 1.5)
D
Discogenic pain confirmed
Provocative discography or high-intensity zone on MRI
I
Isolated disc disease
No stenosis, no multilevel degeneration
S
Sufficient disc height
At least 4mm remaining height for implant placement
C
Conservative treatment failed
Minimum 6 months of non-operative management

Memory Hook:YOUNG-DISC candidates are young patients with isolated disc disease perfect for motion preservation!

Mnemonic

ACCESSTDR Surgical Approach Steps

A
Anterior midline incision
Infraumbilical for L5-S1, extended for L4-5
C
Clear peritoneum laterally
Retroperitoneal dissection to spine
C
Control vessels (mobilize)
Retract aorta/IVC, protect iliac vessels
E
Expose disc space
Between vessels at L5-S1, mobilize veins at L4-5
S
Sympathetic plexus preserve
Protect hypogastric plexus (retrograde ejaculation risk)
S
Secure implant placement
Trial sizing, final implant insertion with imaging

Memory Hook:ACCESS the spine anteriorly with careful vascular control and sympathetic preservation

Overview and Rationale

Lumbar total disc replacement (TDR) is a motion-preserving alternative to spinal fusion for the treatment of degenerative disc disease (DDD). The fundamental goal is to relieve discogenic axial low back pain while maintaining segmental motion at the affected level, theoretically reducing the development of adjacent segment disease (ASD) that commonly follows fusion procedures.

Historical Development

The concept of disc arthroplasty dates to the 1960s with early attempts using stainless steel ball-and-socket designs (Fernström). Modern TDR evolved in the 1980s-1990s with improved biomechanical understanding and materials science. The Charité artificial disc (SB Charité III, DePuy Spine) was the first FDA-approved device in 2004, followed by ProDisc-L (Synthes) in 2006. Multiple other designs have gained European CE marking but not FDA approval in the United States.

Biomechanical Rationale

Adjacent Segment Disease (ASD) is a well-documented phenomenon following spinal fusion, with radiographic changes developing in 8-30% of patients at 10 years and clinical ASD requiring reoperation in 2-4% per year. The pathophysiology involves:

  • Increased intradiscal pressure at adjacent levels (up to 45% increase)
  • Altered kinematics with hypermobility compensation
  • Facet joint overload from loss of normal load sharing
  • Accelerated disc degeneration from abnormal stress concentration

TDR aims to maintain physiologic motion (5-15° flexion-extension per level), preserve normal intradiscal pressure distribution, and reduce stress transfer to adjacent segments. However, whether TDR truly prevents ASD versus fusion remains controversial, with long-term data (greater than 10 years) still accumulating.

Clinical Evidence Summary

Multiple Level I randomized controlled trials comparing TDR to fusion have demonstrated:

  • Non-inferior clinical outcomes at 2, 5, and 10 years
  • Equivalent pain relief and functional improvement
  • Preserved motion at the index level (average 7-10°)
  • Lower reoperation rates at adjacent levels in some studies
  • Similar overall complication rates but different complication profiles

The FDA Investigational Device Exemption (IDE) trials for Charité and ProDisc-L established TDR as a viable alternative for highly selected patients.

Implant Designs and Biomechanics

SB Charité III (DePuy Spine)

Design: Three-component mobile-bearing device with unconstrained ultra-high molecular weight polyethylene (UHMWPE) core between two cobalt-chromium-molybdenum (CoCrMo) endplates.

Biomechanics:

  • Unconstrained motion allows translation and rotation
  • Low constraint may reduce stress on bone-implant interface
  • Self-centering core design intended to maintain center of rotation
  • Potential for core dislocation with improper positioning

Clinical Use:

  • First FDA-approved device (2004)
  • FDA IDE trial showed non-inferiority to circumferential fusion
  • Strict midline placement required to prevent core subluxation
  • Sagittal alignment restoration more challenging than fixed-bearing designs

Outcomes:

  • 73.7% success rate at 2 years in FDA trial
  • Motion preservation: average 7.8° at 5 years
  • Heterotopic ossification rate: 35-65% (may limit motion)

The mobile-bearing design philosophy emphasizes reduced constraint to minimize implant-bone stress, but requires precise surgical technique for optimal outcomes.

ProDisc-L (Synthes/DePuy Synthes)

Design: Two-component semi-constrained device with fixed UHMWPE inlay in inferior cobalt-chromium endplate, articulating with superior convex endplate. Center of rotation anatomically positioned posterior to midline.

Biomechanics:

  • Ball-and-socket articulation with posterior center of rotation
  • Constrained design limits translation, may increase interface stress
  • Keel fixation (inferior component) for rotational stability
  • Better lordosis restoration than mobile-bearing designs

Clinical Use:

  • FDA approved 2006 based on IDE trial vs circumferential fusion
  • Easier surgical technique than mobile-bearing (less positioning critical)
  • Better sagittal balance achievement with lordotic endplate angles
  • Lower reoperation rate than fusion in 5-year follow-up

Outcomes:

  • Non-inferior to fusion at 2 and 5 years
  • Motion preservation: average 9.2° at 5 years
  • Lower adjacent level degeneration rate than fusion (10% vs 28% at 5 years)

The fixed-bearing design prioritizes reproducible biomechanics and ease of surgical implantation, with excellent long-term clinical results.

Maverick (Medtronic)

Design: Two-component metal-on-metal (MOM) articulation with CoCrMo alloy surfaces, avoiding polyethylene entirely.

Theoretical Advantages:

  • No polyethylene wear debris (potential for reduced inflammatory response)
  • Thinner profile allows use in more collapsed disc spaces
  • Greater wear resistance than metal-on-poly designs

Concerns:

  • Metallosis from cobalt and chromium ion release
  • Systemic metal levels elevated in some patients
  • Long-term safety unknown beyond 5-10 years
  • FDA approval limited (humanitarian device exemption only)

Clinical Status:

  • Not FDA approved for general use in US
  • European experience shows good short-term results
  • Declining use due to metallosis concerns following hip MOM issues

Most modern TDR designs have moved away from metal-on-metal articulations due to safety concerns, favoring metal-on-polyethylene bearings.

Implant Selection Considerations

TDR Design Comparison

FeatureMobile-Bearing (Charité)Fixed-Bearing (ProDisc-L)Metal-on-Metal (Maverick)
Components3 (endplates + core)2 (integrated inlay)2 (metal-on-metal)
Motion constraintUnconstrainedSemi-constrainedSemi-constrained
Center of rotationVariable (core migrates)Fixed posteriorFixed central
Lordosis restorationLimitedExcellent (angled endplates)Good
Technique sensitivityHigh (positioning critical)ModerateModerate
Wear concernsUHMWPE wear debrisUHMWPE wear debrisMetallosis
FDA status (US)Approved 2004Approved 2006Humanitarian device only

Patient Selection and Indications

Critical Concept: Patient selection is the single most important determinant of TDR success. Expanding indications beyond strict criteria leads to poor outcomes and high complication rates. When in doubt, fusion is the safer option.

FDA-Approved Indications

Primary Indication: Single-level symptomatic degenerative disc disease at L4-5 or L5-S1 (ProDisc-L approved for single level; Charité approved for single or two-level).

Specific Criteria:

  • Failed conservative treatment: Minimum 6 months of non-operative management including physical therapy, medications, injections
  • Discogenic pain: Concordant pain provocation on discography OR high-intensity zone (HIZ) on T2-weighted MRI
  • Maintained disc height: At least 4mm remaining height (some implants require at least 5mm)
  • Age: Typically 18-60 years (upper age limit varies by study and surgeon preference)
  • No facet arthropathy: Less than Grade 2 facet degeneration on imaging
  • No posterior element disease: Intact pars, no spondylolisthesis
  • Skeletally mature: Closed physes confirmed

Absolute Contraindications

These conditions completely exclude a patient from TDR consideration:

  1. Facet joint arthropathy: Moderate to severe facet degeneration (Fujiwara Grade 2 or higher). TDR does not address facetogenic pain.

  2. Spondylolisthesis: Any grade of degenerative spondylolisthesis. Isthmic spondylolisthesis at any grade. Motion preservation inappropriate with baseline instability.

  3. Spinal stenosis: Central canal stenosis requiring decompression. Lateral recess stenosis. Foraminal stenosis (TDR does not decompress).

  4. Previous surgery at target level: Prior discectomy, laminectomy, or fusion at the same level. Scar tissue and altered anatomy preclude safe TDR placement.

  5. Osteoporosis: T-score less than negative 1.5 on DEXA scan. High risk of endplate subsidence and implant migration.

  6. Active infection: Discitis, osteomyelitis, or systemic infection. Metal implant contraindicated.

  7. Severe disc collapse: Less than 4mm remaining disc height. Insufficient space for implant, altered biomechanics.

  8. Pregnancy: Current pregnancy (relative) or planned pregnancy within 2 years (relative).

  9. Allergy to implant materials: Documented metal allergy to cobalt, chromium, molybdenum, or titanium.

  10. Severe osteopenia: Insufficient bone quality for implant fixation.

Relative Contraindications

These factors increase risk and require careful individualized decision-making:

  • Obesity: BMI over 35 kg per square meter (approach difficulties, increased mechanical loading)
  • Smoking: Active tobacco use (impairs wound healing, may affect outcomes)
  • Multilevel disease: More than two levels of symptomatic DDD (not FDA approved for more than two levels)
  • Age over 60: Limited life expectancy for motion preservation benefit
  • Workers' compensation: Some studies show worse outcomes in compensation cases
  • Litigation: Ongoing injury litigation associated with poor outcomes
  • Psychological factors: Untreated depression, chronic pain syndrome
  • Morbid obesity: BMI over 40 (vascular access challenges)

Ideal Candidate Profile

The perfect TDR candidate:

  • Age 30-50 years old
  • Single-level L4-5 or L5-S1 DDD
  • Discogenic pain confirmed by provocative discography
  • At least 6 months failed conservative care
  • No facet arthropathy (Grade 0-1)
  • Normal sagittal alignment
  • No spondylolisthesis
  • Normal bone density (T-score greater than negative 1.0)
  • Non-smoker
  • BMI less than 30
  • No previous lumbar surgery
  • Psychologically healthy, realistic expectations
  • Not involved in litigation or workers' compensation

In reality, few patients meet all ideal criteria, requiring clinical judgment about which deviations are acceptable.

Imaging Gallery - Patient Selection and Radiographic Outcomes

Vertebral endplate morphology classification system for lumbar disc arthroplasty
Click to expand
Five-type classification system of vertebral endplate morphology relevant to lumbar disc arthroplasty patient selection. Left column displays anatomical illustrations showing: Type I (Flat endplates - optimal for implant seating), Type II (Hooked endplates with osteophytes), Type III (Concave endplates - may provide better implant containment), Type IV (Convex endplates - higher migration risk), and Type V (Combined morphology). Right column shows corresponding lateral radiographs demonstrating each type. Endplate morphology assessment is critical for predicting implant stability, load distribution, and subsidence risk. Severe irregularity or Type IV morphology may be relative contraindications to disc arthroplasty.Credit: Yue JJ et al. via SAS J via Open-i (NIH) (Open Access (CC BY))
Lumbar disc arthroplasty radiographic progression - pre-operative and post-operative comparison
Click to expand
Four-panel lateral lumbar spine radiographic progression demonstrating total disc replacement outcomes. First two panels show pre-operative degenerative disc disease with reduced disc height and endplate changes at the target level. Last two panels demonstrate post-operative appearance following lumbar disc arthroplasty, showing radiopaque metallic components of the implant (superior and inferior endplates with central articulating mechanism) at the treated level. Key radiographic assessment points: implant centered within disc space, adequate endplate coverage for load distribution, restoration of native disc height without over-distraction, and maintenance of segmental lordosis. Serial follow-up radiographs monitor for subsidence, heterotopic ossification, and adjacent segment degeneration.Credit: Marchi L et al. via Int J Spine Surg via Open-i (NIH) (Open Access (CC BY))

Surgical Technique

Vascular Surgery Standby: Many surgeons recommend having a vascular surgeon available or performing the approach, particularly for L4-5 where left common iliac vein mobilization is required. Have vascular instruments and blood products available.

Imaging Analysis

Standing lateral radiograph:

  • Measure disc height at target level (at least 4-5mm required)
  • Assess sagittal alignment (lordosis, pelvic parameters)
  • Identify transitional anatomy (sacralization, lumbarization)
  • Measure implant size needed (AP and lateral dimensions)

MRI review:

  • Confirm disc degeneration (Pfirrmann grade)
  • Rule out facet arthropathy (greater than Grade 2 excludes patient)
  • Identify high-intensity zone (HIZ) if present
  • Rule out stenosis (central, lateral, foraminal)
  • Assess adjacent level disease

CT scan (if needed):

  • Better evaluate facet joints
  • Assess endplate integrity
  • Identify vascular calcification
  • Rule out posterior element pathology

Flexion-extension radiographs:

  • Rule out instability (greater than 3mm translation or greater than 10° angulation)
  • Assess motion at target level (if already fused spontaneously, TDR not indicated)

Implant Sizing

Most systems use trial implants with fluoroscopic verification:

  • Anteroposterior size: Typically 38-50mm (avoid anterior cortex overhang)
  • Mediolateral size: Typically 30-42mm (stay within lateral borders)
  • Height: Match native disc height or restore slightly (avoid over-distraction)
  • Lordotic angle: ProDisc-L offers 6° or 11° options for sagittal balance

Patient Positioning

  • Supine on radiolucent table
  • Slight Trendelenburg (15-20°) to move bowel contents cephalad
  • Arms tucked or positioned on arm boards (not extended over head)
  • Hip flexion minimal to reduce tension on femoral vessels
  • C-arm positioning: Test lateral view before draping (true lateral critical)

Preoperative planning ensures appropriate patient selection, correct implant sizing, and anticipation of anatomical challenges during the anterior approach.

Skin Incision

L5-S1 approach:

  • Vertical midline infraumbilical incision (6-8cm) OR
  • Transverse Pfannenstiel incision 2cm above pubic symphysis (cosmetic)
  • Incision extends through skin, subcutaneous fat, anterior rectus sheath

L4-5 approach:

  • Vertical midline incision extended more cephalad (8-10cm)
  • Higher positioning requires longer incision for vessel mobilization

Retroperitoneal Dissection

Left retroperitoneal approach (standard):

  1. Incise linea alba in midline (avascular plane)
  2. Retract rectus muscles laterally
  3. Identify peritoneum as glistening white membrane
  4. Develop retroperitoneal space by blunt dissection
  5. Mobilize peritoneum medially to expose psoas muscle laterally
  6. Identify ureter running over psoas (protect and retract medially with peritoneum)

Key anatomic landmarks:

  • Psoas muscle (lateral boundary)
  • Peritoneum (medial boundary)
  • Vertebral bodies (posterior)

Vascular Mobilization

At L5-S1:

  • Palpate sacral promontory to identify L5-S1 disc space
  • Identify aortic bifurcation (usually at L4-5 level)
  • Identify middle sacral artery/vein running over L5-S1 disc
  • Ligate middle sacral vessels with clips or ties
  • Access disc space between bifurcation (iliac vessels retracted laterally)

At L4-5:

  • More challenging due to iliac vein location
  • Left common iliac vein crosses anterior to L4-5 disc (must be mobilized)
  • Mobilize vein cranially with gentle dissection
  • Control lumbar segmental vessels if present
  • Higher risk of vascular injury than L5-S1 approach

Sympathetic Plexus Preservation

Hypogastric plexus location:

  • Runs over L5-S1 disc space anteriorly
  • Controls ejaculation in males (sympathetic)
  • Must be protected and retracted laterally with vessel mobilization

Technique:

  • Identify filmy tissue anterior to disc (plexus within)
  • Retract laterally with vessels (usually right side safer)
  • Avoid cautery directly on plexus
  • Gentle retraction (excessive stretch causes neuropraxia)

Retrograde ejaculation risk: 1-5% at L5-S1 (higher with inexperienced surgeons or excessive dissection).

Discectomy

  1. Confirm level with fluoroscopy (count up from sacrum)
  2. Incise annulus with cruciate incision or rectangular window
  3. Remove nucleus with pituitary rongeurs and curettes
  4. Complete discectomy to posterior annulus (avoid posterior longitudinal ligament violation)
  5. Preserve peripheral annulus (contains implant, prevents migration)

Endplate Preparation:

  • Remove cartilaginous endplate with curettes (expose bleeding bone)
  • Preserve bony endplate integrity (avoid violation into vertebral body)
  • Flat endplate preparation essential for implant seating
  • Avoid over-distraction during retractor placement

Implant Positioning

Critical positioning principles:

  • Center implant mediolaterally (equal overhang both sides)
  • Midline sagittal positioning (slightly posterior acceptable for ProDisc-L)
  • No anterior overhang (vascular erosion risk)
  • No posterior placement (spinal canal risk)

Charité-specific:

  • Strict midline positioning required for mobile core
  • Symmetric endplate preparation to allow core centering
  • Posterior position risks core dislocation posteriorly

ProDisc-L-specific:

  • Slightly posterior positioning acceptable (mimics native center of rotation)
  • Keel alignment with midline for rotational control
  • Lordotic angle selection (6° vs 11°) based on sagittal alignment needs

Trialing and Final Implant

  1. Insert trial implant (same size as planned final implant)
  2. Check fluoroscopic positioning (AP and lateral views)
  3. Assess fit (no rocking, no overhang, no endplate violation)
  4. Remove trial and inspect endplates
  5. Insert final implant (typically impacted with gentle mallet)
  6. Confirm final position with fluoroscopy (AP and lateral)

Intraoperative imaging checklist:

  • Implant centered mediolaterally (AP view)
  • No anterior or posterior overhang (lateral view)
  • Parallel to endplates (lateral view)
  • Appropriate height restoration (lateral view)
  • No subsidence (lateral view)

The disc preparation and implant placement are the most technique-sensitive steps, requiring meticulous attention to positioning and endplate preparation.

Hemostasis and Inspection

  1. Remove retractors carefully (inspect vessels for injury)
  2. Achieve meticulous hemostasis (check all dissected planes)
  3. Inspect vessels for intimal tears or hematoma
  4. Check hypogastric plexus area (ensure no stretch injury or bleeding)

Layer-by-Layer Closure

  1. Peritoneum: Usually not closed (self-seals)
  2. Rectus sheath: Close anterior sheath with running absorbable suture (0 or 1 Vicryl)
  3. Subcutaneous layer: Close with absorbable suture (2-0 or 3-0 Vicryl)
  4. Skin: Subcuticular closure (4-0 Monocryl) or staples

No drain typically placed (retroperitoneal approach, minimal dead space).

Postoperative Imaging

  • Lateral and AP radiographs in recovery room
  • Confirm implant position unchanged
  • Rule out immediate subsidence or migration
  • Assess sagittal alignment

Postoperative care focuses on early mobilization, as the anterior approach causes less soft tissue trauma than posterior approaches.

Management Algorithm

📊 Management Algorithm
Management algorithm for Lumbar Disc Arthroplasty
Click to expand
Management algorithm for Lumbar Disc ArthroplastyCredit: OrthoVellum

Complications

Intraoperative Complications

Vascular Injury (1-3%):

  • Most feared complication during anterior approach
  • Iliac vessels at highest risk (vein greater than artery)
  • Left common iliac vein particularly vulnerable at L4-5
  • Management: Immediate vascular surgery consultation, direct repair, possible blood transfusion
  • Prevention: Gentle retraction, good lighting, vascular surgeon availability

Visceral Injury:

  • Bowel perforation: Rare if peritoneum intact (recognize and repair primarily)
  • Ureter injury: Retract with peritoneum, identify and protect
  • Bladder injury: Rare (more common with low transverse incisions)

Neurological Injury:

  • Nerve root injury: Rare (posterior approach risk, not anterior)
  • Sympathetic plexus injury: 1-5% at L5-S1 (retrograde ejaculation in males)

Implant Malposition:

  • Recognized intraoperatively with fluoroscopy
  • Requires removal and repositioning if significant
  • Easier with trial implants (check before final)

Early Postoperative Complications (Less Than 6 Weeks)

Retrograde Ejaculation:

  • Incidence: 1-5% at L5-S1, less than 1% at L4-5
  • Mechanism: Hypogastric plexus stretch or thermal injury
  • Presentation: Inability to ejaculate (orgasm intact, dry ejaculation)
  • Management: Usually permanent (counsel preoperatively), urology referral for fertility issues
  • Prevention: Protect plexus during retraction, avoid cautery near plexus, gentle handling

Wound Complications:

  • Infection: 1-2% (prophylactic antibiotics standard)
  • Hematoma: Rare (retroperitoneal approach less dead space)
  • Dehiscence: Rare with proper fascial closure

Ileus:

  • Incidence: 5-10% (bowel manipulation during retraction)
  • Management: Conservative (NPO, NG tube if needed)
  • Usually resolves within 3-5 days

Subsidence:

  • Early subsidence (first 6 weeks) suggests osteoporosis or endplate violation
  • Imaging: Serial radiographs to monitor (greater than 3mm concerning)
  • Management: Usually observational if asymptomatic; fusion if progressive/symptomatic

Late Complications (Greater Than 6 Weeks)

Heterotopic Ossification (HO):

  • Incidence: 5-60% depending on grading system (clinically significant HO: 5-15%)
  • Mechanism: Ectopic bone formation in paraspinal soft tissues (not in disc space)
  • Classification: McAfee (Grade 0-4), Brooker (Grade 1-4)
  • Impact: May limit motion if severe (Grade 3-4), usually asymptomatic in Grade 1-2
  • Prevention: NSAIDs postoperatively (indomethacin 75mg daily for 6 weeks), low-dose radiation (controversial)
  • Management: Observation if asymptomatic; excision rarely indicated

Facet Degeneration:

  • Progression of facet arthropathy despite motion preservation
  • Suggests poor patient selection (unrecognized facet disease preoperatively)
  • May require fusion if symptomatic

Implant Wear and Loosening:

  • Polyethylene wear: Long-term concern (greater than 10 years)
  • Osteolysis: Rare but reported with wear debris
  • Subsidence: Progressive endplate failure (osteoporosis risk factor)
  • Migration: Very rare with modern designs (keel and teeth fixation)

Core Dislocation (Charité-specific):

  • Mobile core subluxation or dislocation (1-3%)
  • Related to malposition at surgery (non-midline placement)
  • May cause recurrent pain or clicking sensation
  • Diagnosis: Lateral radiographs (core position assessment)

Adjacent Segment Disease:

  • Despite theoretical benefit, ASD still occurs after TDR (lower rate than fusion in some studies)
  • Radiographic ASD: 10-20% at 5 years
  • Symptomatic ASD requiring surgery: 2-4% per year (similar to fusion)

Persistent/Recurrent Pain:

  • Incidence: 10-30% (similar to fusion)
  • Causes: Facetogenic pain (missed at selection), persistent discogenic pain, psychosocial factors
  • Workup: Rule out implant-related issues (subsidence, malposition, HO)
  • Management: Conservative care; fusion if TDR clearly failed

Revision Surgery

Indications:

  • Implant malposition causing symptoms
  • Progressive subsidence with instability
  • Infection
  • Intractable pain despite appropriate patient selection

Revision Options:

  1. Anterior revision TDR: Remove and replace implant (technically demanding)
  2. Anterior implant removal + fusion: Convert to ALIF with cage and screws
  3. Circumferential fusion: Add posterior instrumentation (most common)

Revision Challenges:

  • Severe scar tissue from previous anterior approach
  • Vascular adhesions to vertebral bodies
  • Implant fixation (keels, teeth) makes removal difficult
  • Higher complication rate than primary surgery (5-10% major complications)

Success Rate:

  • Revision to fusion: 60-80% pain relief
  • Revision TDR: Limited data (less predictable outcomes)

Outcomes and Evidence Base

FDA Investigational Device Exemption Trials

I (Randomized Controlled Trial)
📚 Charité IDE Trial (Zigler et al.)
Key Findings:
  • 304 patients randomized: Charité TDR (n=205) vs anterior-posterior fusion (n=99)
  • Primary outcome: Non-inferior at 24 months (57.1% TDR vs 46.5% fusion success)
  • Neurological success: 92.9% TDR vs 88.0% fusion
  • Motion preservation: Average 7.8° at 24 months (TDR) vs 0.9° (fusion)
  • Overall success rate: 63.2% TDR vs 53.1% fusion (statistically significant)
  • Adverse events: Similar overall rates between groups
Clinical Implication: Established Charité TDR as non-inferior to fusion for single-level DDD, leading to FDA approval in 2004. Success depended heavily on strict patient selection criteria.
Source: Spine J 2007; Spine 2005

I (Randomized Controlled Trial)
📚 ProDisc-L IDE Trial (Zigler et al., Delamarter et al.)
Key Findings:
  • 236 patients randomized: ProDisc-L (n=161) vs circumferential fusion (n=75)
  • Single-level L4-5 or L5-S1 DDD with failed conservative care
  • Primary endpoint: Non-inferior at 24 months (53.4% TDR vs 40.8% fusion)
  • ODI improvement: 23.5 points (TDR) vs 19.1 points (fusion)
  • VAS improvement: 4.5 cm (TDR) vs 3.8 cm (fusion)
  • Motion preservation: Average 9.2° at 24 months
  • Reoperation rate: Lower in TDR group (3.7% vs 9.1%)
Clinical Implication: Demonstrated ProDisc-L superiority to fusion in pain relief and function, with lower reoperation rates. Led to FDA approval in 2006.
Source: Spine 2007; SAS J 2008

II (Prospective Cohort)
📚 Long-Term ProDisc-L Follow-Up (Zigler et al.)
Key Findings:
  • 5-year follow-up of ProDisc-L IDE trial participants
  • Sustained clinical improvement: ODI 17.9 (baseline 51.0)
  • Maintained motion: Average 7.4° at 5 years
  • Adjacent segment reoperation: 1.9% (TDR) vs 4.0% (fusion)
  • Overall reoperation: 5.6% (TDR) vs 9.1% (fusion)
  • Device-related complications: Heterotopic ossification 8.8%, subsidence 4.4%
Clinical Implication: Confirmed durability of TDR outcomes to 5 years with sustained motion preservation and lower adjacent segment reoperation rate than fusion.
Source: Spine 2012

I (Meta-Analysis of RCTs)
📚 Systematic Review: TDR vs Fusion (Jacobs et al.)
Key Findings:
  • 6 RCTs included (1,220 patients total)
  • Overall clinical success: No significant difference (RR 1.08, p=0.09)
  • ODI improvement: Slightly favored TDR (mean difference 3.18 points)
  • Complication rates: No significant difference overall
  • Reoperation rates: Significantly lower in TDR (RR 0.67, p=0.02)
  • Adjacent segment disease: Lower radiographic rate in TDR (RR 0.64, p=0.02)
Clinical Implication: Meta-analysis confirmed TDR non-inferiority to fusion with potential advantages in reoperation and adjacent segment disease rates.
Source: Spine 2013

Long-Term Outcomes (Greater Than 10 Years)

10-Year ProDisc-L Data (limited published data):

  • Sustained clinical improvement in 70-80% of patients
  • Motion preservation maintained (average 6-8° flexion-extension)
  • Adjacent level surgery rate: approximately 10% at 10 years
  • Device survival (no revision): greater than 90%

Charité Long-Term Data:

  • More variable outcomes than ProDisc-L
  • Technique-sensitive (mobile-bearing positioning critical)
  • Heterotopic ossification increased over time (may limit motion)

Comparison to Fusion Outcomes

TDR vs Fusion: Comparative Outcomes

Outcome MeasureTDR (Average)Fusion (Average)Clinical Significance
Pain relief (VAS)4-5 cm improvement3-4 cm improvementSimilar magnitude
Function (ODI)20-25 point improvement18-22 point improvementSimilar magnitude
Motion preservation6-10° maintained0-2° (fused)TDR preserves motion
Adjacent segment surgery 5yr2-4%4-8%Lower with TDR
Overall reoperation 5yr5-8%8-12%Lower with TDR
Heterotopic ossification5-15% clinically significantN/ATDR-specific complication
Retrograde ejaculation1-5% (L5-S1)Rare with posteriorTDR higher (anterior approach)

Predictors of Success

Positive Predictors:

  • Age under 50 years
  • Single-level disease
  • Normal BMI (less than 30)
  • No facet arthropathy
  • No previous surgery
  • Non-smoker
  • No litigation/workers' compensation
  • Realistic expectations

Negative Predictors:

  • Multi-level disease
  • Facet arthropathy (even mild)
  • BMI over 35
  • Active smoking
  • Previous surgery at level
  • Compensation/litigation
  • Psychological comorbidities

Exam Viva Scenarios

Practice these scenarios to excel in your viva examination

VIVA SCENARIOStandard

Scenario 1: Ideal TDR Candidate Counseling

EXAMINER

"A 42-year-old accountant presents with 18 months of chronic low back pain. MRI shows L5-S1 disc degeneration with high-intensity zone (HIZ) and maintained disc height. No facet arthropathy. Failed 8 months of physiotherapy and epidural injections. He asks about disc replacement after researching online. How do you counsel him?"

EXCEPTIONAL ANSWER
This patient appears to meet criteria for consideration of lumbar total disc replacement at L5-S1. I would take a systematic approach to counseling. First, I would confirm he is an appropriate candidate: single-level disease at L5-S1, age under 60, failed conservative care for over 6 months, discogenic pain confirmed by MRI showing high-intensity zone, no facet arthropathy, no spondylolisthesis, and maintained disc height. I would review his imaging to rule out any contraindications including stenosis, previous surgery, or poor bone quality. Assuming he meets strict criteria, I would explain that TDR is a motion-preserving alternative to fusion. The goal is to relieve his discogenic pain while maintaining motion at L5-S1, which theoretically reduces stress on adjacent levels and may lower the risk of adjacent segment disease compared to fusion. I would explain the surgery involves an anterior retroperitoneal approach, requiring working around major blood vessels, with vascular injury being the main surgical risk. Specific to L5-S1, there is a 1-5% risk of retrograde ejaculation from sympathetic plexus injury, which is usually permanent and affects fertility (important to discuss before surgery). I would present the evidence: FDA trials showed TDR is non-inferior to fusion at 2, 5, and 10 years, with similar pain relief and functional improvement but potentially lower reoperation rates. However, TDR is more technique-sensitive and has different complications including heterotopic ossification which may limit motion over time. Fusion is well-established with predictable outcomes but eliminates motion permanently. Given his young age, single-level disease, and meeting strict criteria, both options are reasonable. I would explain that patient selection is critical - outcomes are only good when indications are strictly followed. If he had any facet arthropathy, spondylolisthesis, or previous surgery, fusion would be strongly preferred. I would arrange further imaging if needed (standing lateral radiographs, CT to assess facets and bone quality), discuss risks and benefits in detail, and ensure he has realistic expectations about pain relief (not 100% guarantee).
KEY POINTS TO SCORE
Confirm strict patient selection criteria before offering TDR
Explain motion preservation rationale and theoretical ASD benefit
Discuss vascular approach risks and retrograde ejaculation (L5-S1 specific)
Present evidence: non-inferior to fusion in RCTs, potentially lower reoperation
Ensure realistic expectations and informed consent
COMMON TRAPS
✗Offering TDR without thoroughly ruling out facet disease
✗Not mentioning retrograde ejaculation risk (important for young males)
✗Overselling ASD prevention (theoretical benefit, not proven definitively)
✗Not discussing fusion as equally valid alternative
LIKELY FOLLOW-UPS
"What are the absolute contraindications to TDR?"
"How would you approach L4-5 differently than L5-S1?"
"What would you do if intraoperative fluoroscopy shows implant malposition?"
VIVA SCENARIOStandard

Scenario 2: Contraindication Recognition

EXAMINER

"A 38-year-old woman with chronic low back pain is referred by her GP requesting disc replacement at L4-5. Her MRI shows disc degeneration at L4-5 with Grade 2 facet arthropathy (moderate facet joint degeneration). She had a microdiscectomy at L4-5 three years ago. How do you manage?"

EXCEPTIONAL ANSWER
This patient has two absolute contraindications to lumbar disc replacement that exclude her from consideration: previous surgery at the target level (L4-5 microdiscectomy three years ago) and moderate facet arthropathy (Grade 2). I would counsel her that disc replacement is not an appropriate option for her condition. First, I would explain that the previous microdiscectomy has altered the anatomy at L4-5 with scar tissue formation and potentially compromised the disc space and annulus, making TDR implantation unsafe and unlikely to succeed. More importantly, her Grade 2 facet arthropathy means that a significant portion of her pain is likely facetogenic rather than purely discogenic. TDR only addresses discogenic pain by replacing the disc - it does nothing for facet joint pain. If we performed TDR in this setting, her facet pain would persist or worsen, leading to a poor outcome. I would explain that these are not relative contraindications that we might work around - they are absolute contraindications based on biomechanics and outcomes data. Patients with facet disease or previous surgery at the target level have consistently poor outcomes with TDR in published studies. I would then discuss appropriate alternatives. If her pain is predominantly discogenic and she has failed extensive conservative care, a fusion procedure (TLIF or ALIF) would be more appropriate as it addresses both the disc and provides fixation for any facet-related instability. The fusion also accounts for the altered anatomy from her previous discectomy. If her pain is predominantly facetogenic, we might consider facet interventions (medial branch blocks, radiofrequency ablation) or possibly fusion if there is demonstrable instability. I would arrange thorough clinical assessment to determine the primary pain generator (facet versus disc), possibly including diagnostic facet injections, and formulate a treatment plan based on that assessment. The key message is that patient selection is critical for TDR success, and expanding beyond strict criteria leads to predictably poor outcomes.
KEY POINTS TO SCORE
Recognize absolute contraindications: previous surgery + facet arthropathy
Explain why TDR would fail (doesn't address facet pain, altered anatomy)
Counsel that these are not negotiable - absolute contraindications
Offer appropriate alternatives (fusion if indicated)
Emphasize importance of strict patient selection for TDR success
COMMON TRAPS
✗Considering TDR despite clear contraindications
✗Not explaining why facet arthropathy excludes patient
✗Failing to offer appropriate alternative (fusion)
✗Not emphasizing that expanding indications leads to poor outcomes
LIKELY FOLLOW-UPS
"How would you differentiate discogenic versus facetogenic pain?"
"What fusion technique would you recommend for this patient?"
"What if she insists on TDR despite your recommendation against it?"
VIVA SCENARIOAdvanced

Scenario 3: Intraoperative Vascular Injury

EXAMINER

"You are performing an L4-5 disc replacement and mobilizing the left common iliac vein when you notice pulsatile bleeding from the vein. The access surgeon is not in the room but is in the hospital. How do you manage?"

EXCEPTIONAL ANSWER
This is a vascular emergency requiring immediate, systematic management. My priorities are to control hemorrhage, protect the patient, and obtain definitive vascular repair. Immediately, I would apply direct pressure with a vascular sponge or laparotomy pad to the injury site while my assistant calls for the access surgeon STAT and notifies anesthesia of the vascular injury. I would ask for additional help (another surgeon if available), ensure large-bore IV access is functioning, and request blood products (type-specific or O-negative if massive bleeding). While maintaining pressure, I would ensure the patient is adequately resuscitated - communicate with anesthesia about blood pressure, heart rate, and need for fluid/blood administration. I would extend the incision if needed for better exposure and proximal/distal control. With proximal and distal control achieved (either by direct pressure or vascular clamps if I am trained), I would await the vascular surgeon's arrival - typically within minutes if in-house. I would not attempt definitive repair myself unless I have specific vascular training, as improper repair can worsen the injury. The vascular surgeon would perform direct repair (lateral venorrhaphy for small defect, patch repair for larger defect, or rarely ligation if repair not possible - the left common iliac vein can sometimes be ligated without severe consequences if the right side is intact). If the vascular surgeon is significantly delayed and bleeding cannot be controlled with pressure, I would consider temporary measures: direct pressure with packing, proximal control with clamps if safe, or attempting direct suture of the defect if I can visualize it clearly (6-0 or 7-0 Prolene vascular suture with gentle technique to avoid tearing the vein further). After vascular control is achieved and the injury repaired, I would abort the disc replacement procedure - patient safety is paramount. I would close in standard fashion and plan for staged TDR at a later date once the patient has recovered, or potentially convert to a posterior fusion approach instead. Postoperatively, I would monitor for compartment syndrome of the lower extremities (venous occlusion), signs of ongoing bleeding (falling hemoglobin, hemodynamic instability), and lower extremity perfusion. I would document the incident thoroughly, discuss with the patient postoperatively about the complication and plan going forward, and complete an incident report. This complication reinforces the importance of having vascular access readily available for anterior lumbar surgery.
KEY POINTS TO SCORE
Immediate direct pressure to control hemorrhage
Call vascular surgeon STAT and activate resuscitation protocol
Ensure adequate IV access, notify anesthesia, order blood products
Do not attempt definitive repair unless specifically trained
Abort disc replacement procedure once vascular control achieved
Postoperative monitoring for compartment syndrome and ongoing bleeding
COMMON TRAPS
✗Attempting vascular repair without proper training (can worsen injury)
✗Continuing with disc replacement after major vascular injury (unsafe)
✗Not calling for help immediately (vascular surgery, anesthesia, blood bank)
✗Panicking instead of systematic approach to hemorrhage control
LIKELY FOLLOW-UPS
"What would you tell the patient postoperatively about this complication?"
"Would you still recommend TDR after this complication is resolved?"
"How could this complication have been prevented?"
VIVA SCENARIOAdvanced

Scenario 4: Revision TDR to Fusion

EXAMINER

"A 48-year-old woman had L5-S1 ProDisc-L performed 3 years ago at an outside institution. She initially did well for 12 months but now has recurrent severe low back pain. Imaging shows the implant is well-positioned with no subsidence, but there is progressive Grade 3 facet arthropathy at L5-S1 and Grade 2 at L4-5. She has failed injections and medications. She asks what can be done. How do you manage?"

EXCEPTIONAL ANSWER
This is a case of failed TDR due to what appears to be progression of facet arthropathy that was either present but unrecognized at the time of index surgery, or has developed since. The TDR implant itself appears well-positioned and functioning, but is not addressing her facetogenic pain. This illustrates the critical importance of patient selection for TDR - facet disease is an absolute contraindication because TDR does not treat facet pain. I would first complete a thorough assessment. Clinically, I would examine her to confirm facet-mediated pain (paravertebral tenderness, pain with extension and rotation, facet loading tests). I would review her original imaging if available to determine if facet disease was present pre-operatively and missed, or if this is true progression. If there is any doubt about the pain generator, I would consider diagnostic facet injections at L5-S1 to confirm facetogenic versus residual discogenic pain, though with Grade 3 facet arthropathy the diagnosis is fairly clear. I would counsel her that her pain is coming from the facet joints, not the disc that was replaced. The TDR cannot address facet pain. Her options are limited: continued conservative management with activity modification, analgesics, and possibly radiofrequency ablation of the medial branches supplying the L5-S1 facets (temporary relief only), or revision surgery. For revision surgery, I would explain that this is a major undertaking. The options are: (1) Anterior revision to remove the ProDisc-L and convert to ALIF with cage and supplemental posterior instrumentation (circumferential fusion), or (2) posterior-only fusion (TLIF or posterolateral fusion with pedicle screws) leaving the TDR in place as anterior column support. The second option is less morbid (avoids repeat anterior approach with vascular risks and scar tissue). I would favor posterior fusion (TLIF) with pedicle screw fixation, leaving the ProDisc-L in situ. This addresses the facet pain by eliminating motion and stabilizing the segment. The existing TDR serves as anterior column support, reducing the need for an interbody cage (though some surgeons still place a cage). I would counsel about risks: this is revision surgery with higher complication rates than primary surgery (5-10% major complications), uncertain pain relief (60-80% achieve significant improvement), and adjacent segment disease risk (now fusing after motion preservation). Success depends on confirming facets are the primary pain generator. I would set realistic expectations, ensure she understands this is salvage surgery for a failed procedure, and consider second opinion or multidisciplinary pain evaluation before proceeding. This case highlights that TDR is not reversible in the simple sense - revision is complex and outcomes are less predictable than primary surgery.
KEY POINTS TO SCORE
Recognize failed TDR due to facet arthropathy (pain generator not addressed)
Distinguish facetogenic from discogenic pain (exam, imaging, possibly injections)
Revision options: anterior removal + fusion OR posterior fusion leaving TDR in place
Favor posterior fusion (TLIF) as less morbid than repeat anterior approach
Counsel realistic expectations: 60-80% improvement, higher complication risk
This illustrates importance of strict patient selection (no facet disease) for TDR
COMMON TRAPS
✗Assuming the TDR implant itself has failed (it appears well-positioned)
✗Not recognizing facet disease as cause of pain
✗Offering implant removal as first-line (higher morbidity)
✗Overpromising outcomes for revision surgery (less predictable than primary)
LIKELY FOLLOW-UPS
"How would you perform the posterior fusion leaving the TDR in place?"
"What would you tell her about whether she should have had TDR in the first place?"
"How do you counsel a patient considering TDR about this potential outcome?"

MCQ Practice Points

Contraindication Recognition

Q: Which of the following is an absolute contraindication to lumbar total disc replacement?

A) Age 55 years B) BMI 32 C) Fujiwara Grade 2 facet arthropathy D) Two-level disease (L4-5 and L5-S1) E) Non-union of previous wrist fracture

Answer: C) Fujiwara Grade 2 facet arthropathy

Explanation: Moderate to severe facet arthropathy (Grade 2 or higher) is an absolute contraindication to TDR because the facet joints are a pain generator that TDR does not address. Patients with facet disease have consistently poor outcomes with TDR. Age 55 is acceptable (under 60 preferred). BMI 32 is a relative contraindication but not absolute. Two-level disease is FDA-approved for some devices (Charité). Previous wrist fracture is irrelevant unless it indicates systemic bone disease.

Vascular Approach Anatomy

Q: During anterior approach to L4-5 for disc replacement, which structure must typically be mobilized to access the disc space?

A) Right common iliac artery B) Left common iliac vein C) Inferior vena cava D) Abdominal aorta E) Middle sacral artery

Answer: B) Left common iliac vein

Explanation: The left common iliac vein crosses anterior to the L4-5 disc space and must be mobilized cranially (superiorly) to access L4-5. This makes L4-5 approach more challenging and higher vascular risk than L5-S1, where access is between the bifurcation of the great vessels. The middle sacral artery is ligated at L5-S1, not L4-5. The IVC and aorta are more proximal (cephalad) and typically do not require mobilization.

Sympathetic Plexus Injury

Q: A 40-year-old male underwent L5-S1 disc replacement and reports inability to ejaculate 6 weeks postoperatively. What is the most likely cause?

A) Spinal cord injury B) Cauda equina syndrome C) Hypogastric plexus injury D) Pudendal nerve injury E) Psychological reaction to surgery

Answer: C) Hypogastric plexus injury

Explanation: Retrograde ejaculation from hypogastric (sympathetic) plexus injury occurs in 1-5% of L5-S1 TDR cases. The hypogastric plexus runs over the L5-S1 disc space anteriorly and can be stretched or injured during vessel mobilization. The patient has normal orgasm but dry ejaculation (semen goes into bladder instead of urethra). This is usually permanent. Spinal cord ends at L1-2 (not injured at L5-S1). Cauda equina would cause bowel/bladder/saddle numbness. Pudendal nerve injury would affect sensation and erection, not just ejaculation.

Implant Design Differences

Q: What is the primary biomechanical difference between Charité and ProDisc-L lumbar disc replacements?

A) Charité is cemented; ProDisc-L is uncemented B) Charité has mobile polyethylene core; ProDisc-L has fixed core C) Charité is metal-on-metal; ProDisc-L is metal-on-polyethylene D) Charité requires posterior instrumentation; ProDisc-L does not E) Charité is placed posteriorly; ProDisc-L is placed anteriorly

Answer: B) Charité has mobile polyethylene core; ProDisc-L has fixed core

Explanation: The Charité is a mobile-bearing design with a free-floating polyethylene core between two metal endplates (unconstrained). The ProDisc-L is a fixed-bearing design with the polyethylene inlay fixed to the inferior endplate and articulating with the superior endplate (semi-constrained, ball-and-socket). Both are uncemented (rely on teeth/keel fixation). Both are metal-on-polyethylene (not metal-on-metal). Both are placed via anterior approach. Neither requires posterior instrumentation.

Adjacent Segment Disease Theory

Q: What is the theoretical advantage of TDR over fusion regarding adjacent segment disease?

A) TDR decompresses adjacent neural elements B) TDR maintains motion, reducing stress transfer to adjacent levels C) TDR strengthens adjacent disc collagen D) TDR prevents facet degeneration at adjacent levels E) TDR increases disc height at adjacent levels

Answer: B) TDR maintains motion, reducing stress transfer to adjacent levels

Explanation: The biomechanical rationale for TDR is that fusion eliminates motion at the index level, transferring increased stress (intradiscal pressure up to 45% higher, altered kinematics) to adjacent segments, potentially accelerating degeneration. TDR preserves motion (5-15° per level), maintaining more physiologic load distribution and theoretically reducing adjacent segment stress. However, this benefit remains theoretical - while some studies show lower radiographic ASD rates with TDR, symptomatic ASD requiring surgery is similar between TDR and fusion in most long-term studies. TDR does not directly decompress, strengthen, or increase height at adjacent levels.

Australian Context

Clinical Practice in Australia

Availability: Lumbar TDR is performed at specialized spine centers in major Australian cities. Access is more limited than in Europe or the United States due to stricter patient selection and fewer trained surgeons.

Regulatory Status:

  • TGA (Therapeutic Goods Administration) approval for multiple TDR devices
  • Charité and ProDisc-L are available but not commonly used
  • Newer devices (Activ-L, M6) have limited Australian experience

Medicare and Private Insurance:

  • Private insurance coverage varies by fund and policy
  • Out-of-pocket costs can be significant (specialist implants)

Australian Orthopaedic Association (AOA) Position

The AOA recognizes TDR as an alternative to fusion for highly selected patients but emphasizes:

  • Strict patient selection essential for good outcomes
  • Long-term data still accumulating (greater than 10 years)
  • Fusion remains gold standard for most degenerative disc disease
  • Surgeon training and experience critical for safety and outcomes

Published Australian Data

Limited published Australian series on TDR outcomes. Most evidence comes from international (particularly European and US FDA) trials. Australian surgeons generally follow FDA IDE trial criteria for patient selection.

Clinical Trends

  • Declining use of TDR in Australia over past 5 years
  • Fusion techniques (TLIF, ALIF, lateral) have become more refined and predictable
  • Concerns about long-term TDR durability and revision complexity
  • Patient selection challenges (few patients meet strict criteria)
  • Medicolegal considerations (informed consent critical for newer technology)

eTG Antibiotic Guidelines

For lumbar TDR (implant surgery):

  • Prophylactic antibiotics: Cefazolin 2g IV at induction (or vancomycin if MRSA risk)
  • Surgical site infection rate: Less than 2% with appropriate prophylaxis
  • Prosthetic joint infection protocols apply if infection develops (similar to arthroplasty)

Future Directions in Australia

  • Registry data collection (potential inclusion in AOA National Joint Replacement Registry)
  • Long-term outcome studies of Australian TDR cohorts
  • Patient selection refinement based on predictive models
  • Comparison to modern fusion techniques (TLIF, lateral, minimally invasive)

The Australian spine surgery community remains cautious about TDR, favoring proven fusion techniques for most patients while recognizing TDR as a valid option for the rare ideal candidate.

LUMBAR DISC ARTHROPLASTY

High-Yield Exam Summary

Indications (Must Meet ALL)

  • •Single or two-level DDD at L4-5 or L5-S1 (FDA approved)
  • •Discogenic pain confirmed (provocative discography or HIZ on MRI)
  • •Failed conservative treatment minimum 6 months
  • •Age typically under 60 years (young patient, long benefit)
  • •Maintained disc height (at least 4-5mm for implant placement)
  • •NO facet arthropathy (Grade 0-1 only, Grade 2+ excludes)
  • •NO spondylolisthesis, stenosis, or previous surgery at level

Contraindications (FOSSILS)

  • •Facet arthropathy (major pain generator not addressed)
  • •Osteoporosis (T-score less than negative 1.5, subsidence risk)
  • •Spondylolisthesis (greater than Grade I, instability)
  • •Stenosis (spinal, needs decompression not motion)
  • •Infection (active or previous at target level)
  • •Levels more than 2 (multi-level disease not approved)
  • •Surgery previous at level (scar tissue, altered anatomy)

Implant Designs

  • •Mobile-bearing (Charité): 3-piece, unconstrained, free poly core
  • •Fixed-bearing (ProDisc-L): 2-piece, semi-constrained, ball-and-socket
  • •Metal-on-metal (Maverick): No polyethylene, metallosis concerns
  • •All use teeth/keel fixation (no cement), anterior approach only

Surgical Approach (ACCESS)

  • •Anterior midline incision (infraumbilical for L5-S1, extended L4-5)
  • •Clear peritoneum laterally (retroperitoneal dissection)
  • •Control vessels: L5-S1 between bifurcation; L4-5 mobilize left iliac vein
  • •Expose disc space (ligate middle sacral vessels at L5-S1)
  • •Sympathetic plexus preserve (hypogastric, retrograde ejaculation risk)
  • •Secure implant (midline positioning critical, especially Charité)

Complications

  • •Vascular injury 1-3% (iliac vessels, higher at L4-5)
  • •Retrograde ejaculation 1-5% at L5-S1 (hypogastric plexus injury)
  • •Heterotopic ossification 5-15% clinically significant (may limit motion)
  • •Subsidence (early: osteoporosis; late: endplate failure)
  • •Implant malposition (check intraop fluoro, reposition if needed)
  • •Revision difficult (scar, vascular adhesions, implant removal challenging)

Evidence and Outcomes

  • •FDA IDE trials: Non-inferior to fusion at 2, 5, 10 years
  • •Motion preservation: 5-15° per level (average 7-10° long-term)
  • •Adjacent segment surgery: Lower rate than fusion (2-4% vs 4-8% at 5yr)
  • •Overall success: 70-80% in selected patients (patient selection critical)
  • •Reoperation rate: 5-8% at 5 years (lower than fusion 8-12%)

Exam Pearls

  • •Ideal candidate: Young (under 60), single-level L4-5/L5-S1, no facet disease
  • •Never offer TDR if facet arthropathy (absolute contraindication)
  • •L4-5 approach harder than L5-S1 (left iliac vein mobilization)
  • •Counsel males about retrograde ejaculation risk before L5-S1 TDR
  • •Non-inferior to fusion but different complication profile
  • •Strict patient selection = key to success (expanding criteria = poor outcomes)
Quick Stats
Reading Time136 min
Related Topics

Atlantoaxial Arthritis

Baastrup Disease (Kissing Spine Syndrome)

Bertolotti Syndrome (Lumbosacral Transitional Vertebra)

Cervical Facet Arthropathy